Here is data from biotech value board supporting the assertion.
Quote: 22% of CP-CML patients experienced an arterial thrombotic serious adverse event (SAE), and 27 percent of CP-CML patients experienced any arterial thrombotic event
Iclusig arterial thrombotic SAE rate continues to rise even after significant dose reduction. Compare the above numbers from 38-month follow-up against ASCO2014 30-month follow-up of 16% arterial thrombotic SAE, and 23% any arterial thrombotic event.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.